Critical Review: Trevena (NASDAQ:TRVN) & Amarin (NASDAQ:AMRN)

Trevena (NASDAQ:TRVN) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Earnings & Valuation

This table compares Trevena and Amarin”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443,000.00	0.00	-$40.29 million	($47.04)	-0.00
Amarin	$213.65 million	1.38	-$38.80 million	($0.99)	-14.11

Amarin has higher revenue and earnings than Trevena. Amarin is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Trevena and Amarin, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0	0	0	0	0.00
Amarin	2	1	0	0	1.33

Amarin has a consensus price target of $13.00, indicating a potential downside of 6.94%. Given Amarin’s stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Trevena.

Insider and Institutional Ownership

13.6% of Trevena shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Trevena and Amarin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Amarin	-14.56%	-0.20%	-0.14%

Volatility and Risk

Trevena has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500. Comparatively, Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Summary

Amarin beats Trevena on 10 of the 13 factors compared between the two stocks.

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.